endo-BCN-Val-Cit-PAB-MMAE is a synthetic antibody drug conjugate (ADC) coupled to a BCN group. It contains a a protease-sensitive Val-Cit dipeptide and a MMAE payload. The MMAE is a synthetic antineoplastic agent which can be attached to a monoclonal antibody (mAb) that directs it toward cancer cells. The BCN group can react with azide-tagged compounds or biomolecules.
Usually ships within 24 hours.